☆ 4.7 Article

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma

Yael C. Cohen et al.

Summary: In this study, daratumumab plus cetrelimab was evaluated in patients with relapsed or refractory multiple myeloma, showing no new safety concerns. However, the potential clinical benefit of this combination remains uncertain, indicating the need for further research.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

添加到收藏夹

Article Urology & Nephrology

CD38 in Advanced Prostate Cancers

Christina Guo et al.

Summary: The study characterized CD38 expression in prostate cancer patients and its association with clinical outcomes. CD38 was mainly expressed on immune cells and associated with immune signaling pathways and immunosuppressive mechanisms.

EUROPEAN UROLOGY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis

Anne J. Paccaly et al.

Summary: This study outlined the dosing strategy of Cemiplimab IV and supported the transition from BW-based dosing to fixed dosing through PopPK modeling and simulations. The study found that the new fixed dose of Cemiplimab was similar to the previous weight-based dosing at steady state, demonstrating the efficacy of dose optimization based on PopPK modeling.

ADVANCES IN THERAPY (2021)

添加到收藏夹

Article Oncology

CD38 identifies pre-activated CD8+T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer

Pin Wu et al.

Summary: The study revealed a correlation between CD38 expression and survival and immune infiltration levels in non-small cell lung cancer (NSCLC), with CD38+ CD8+ T cells in tumors showing higher expression levels of cytotoxic molecules, cytokines, and PD-1 compared to CD38- CD8+ T cells. Additionally, the PD-1+ subset of CD38+ CD8+ T cells exhibited higher levels of activated markers than PD-1+ CD38- CD8+ T cells, and reactivated CD38+ CD8+ T cells in vitro expressed higher levels of CD103, IFN-gamma, TNF-alpha, and perforin compared to CD38- CD8+ T cells. Finally, it was observed that CD38+ CD8+ T cells isolated from tumors could be reinvigorated by anti-PD-1 in vitro, suggesting a potential role for PD-1 blockade in enhancing anti-tumor potency and reversing exhausted phenotype in NSCLC.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Review Oncology

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer

Jingjing Qu et al.

Summary: The use of PD-1/PD-L1 inhibitors is the standard therapy for NSCLC patients, prolonging survival without significant side effects. However, the lack of optimal prognostic markers remains a challenge for further clinical applications.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

CD38 as immunomodulator in cancer

Yanli Li et al.

FUTURE ONCOLOGY (2020)

添加到收藏夹

Article Immunology

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

Chen Zhu et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Oncology

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

Christie P. M. Verkleij et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer

Harry J. Han et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Laura Moreno et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer

Matthew D. Tucker et al.

CANCER MEDICINE (2019)

添加到收藏夹

Article Oncology

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade

Limo Chen et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Article Oncology

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma

Xiaoyan Feng et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Howard I. Scher et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer

Julie N. Graff et al.

ONCOTARGET (2016)

添加到收藏夹

Review Medical Laboratory Technology

CD38 and CD157: A long journey from activation markers to multifunctional molecules

Valeria Quarona et al.

CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.